Several brokers are unanimous in recommending a "buy" on shares of Praram 9 Hospital, or PR9, expecting second-half operating results to grow by leaps and bounds on the momentum of the high season in the third quarter, a period when influenza spreads and more domestic patients return to use services. At the same time, foreign customer groups, especially from the Middle East, Myanmar and Laos, have begun traveling back for continuing treatment. The health check-up service portfolio also remains strong, and the company is pressing ahead with expanding its new customer base in China through Premium IVF services, as well as returning to market to Indonesian customer groups late this year. Prasit Rattanakitkamon, assistant managing director at Asia Plus Securities, gives a "buy" recommendation with a target price of 23 baht per share, while Teerapol Udomwet, an analyst at Kiatnakin Phatra Securities, gives a target price of 24.50 baht per share, and an analysis by KGI Securities Thailand gives a target price of 21 baht per share. PR9 shares closed yesterday at 19.30 baht.
Praram 9 Hospital Public Company LimitedMultiple brokers unanimously recommend buying PR9 with target prices of 21-24.50 baht, above its 19.30 baht close.
